Albert Cha Net Worth

The estimated Net Worth of Albert Cha is at least $298 mil dollars as of 11 September 2023. Albert Cha owns over 18,000 units of KalVista Pharmaceuticals Inc stock worth over $192,960 and over the last 9 years he sold KALV stock worth over $0. In addition, he makes $104,919 as Independent Director at KalVista Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Albert Cha KALV stock SEC Form 4 insiders trading

Albert has made over 9 trades of the KalVista Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 18,000 units of KALV stock worth $134,820 on 11 September 2023.

The largest trade he's ever made was buying 1,058,824 units of KalVista Pharmaceuticals Inc stock on 10 September 2018 worth over $18,000,008. On average, Albert trades about 121,056 units every 138 days since 2015. As of 11 September 2023 he still owns at least 18,000 units of KalVista Pharmaceuticals Inc stock.

You can see the complete history of Albert Cha stock trades at the bottom of the page.

Albert Cha biography

Dr. Albert Cha M.D. Ph.D. serves as Independent Director of the Company. Dr. Cha has served as a member of our Board since the consummation of the Carbylan Therapeutics, Inc. transaction in 2016. Dr. Cha served as a member of the Carbylan board of directors starting in November 2007. In September 2000, Dr. Cha joined Vivo Capital, a healthcare investment firm, where he has served in various positions. Dr. Cha currently serves as a member of the boards of directors of Ascendis Pharma A/S and several privately-held biotechnology and medical device companies. During the past five years, he also served as a member of the boards of directors of Biohaven Pharmaceutical Holding Company Ltd., Aclaris Therapeutics, Inc., Sierra Oncology, Inc. (formerly ProNAi Therapeutics, Inc.) and AirXpanders, Inc. Dr. Cha received a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles. Cha is qualified to serve on our Board because of his medical background, venture capital experience and significant experience serving as a director of other life sciences companies.

What is the salary of Albert Cha?

As the Independent Director of KalVista Pharmaceuticals Inc, the total compensation of Albert Cha at KalVista Pharmaceuticals Inc is $104,919. There are 10 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of $1,731,160.

How old is Albert Cha?

Albert Cha is 48, he's been the Independent Director of KalVista Pharmaceuticals Inc since 2007. There are 12 older and 5 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.

What's Albert Cha's mailing address?

Albert's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at KalVista Pharmaceuticals Inc

Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ..., eRajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.

What does KalVista Pharmaceuticals Inc do?

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Complete history of Albert Cha stock trades at Aclaris Therapeutics Inc, KalVista Pharmaceuticals Inc, Biohaven Ltd, eMenlo Therapeutics

KalVista Pharmaceuticals Inc executives and stock owners

KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Thomas Crockett,
  Chief Executive Officer, Director
• Edward Feener,
  Chief Scientific Officer
• Benjamin Palleiko,
  Chief Financial Officer, Chief Business Officer
• Thomas Andrew Crockett M.B.A.,
  CEO & Director
• Christopher Yea,
  Chief Development Officer
• Benjamin L. Palleiko,
  Chief Bus. Officer & CFO
• Dr. Christopher M. Yea Ph.D.,
  Chief Devel. Officer
• Martin Edwards,
  Independent Chairman of the Board
• Edward Unkart,
  Independent Director
• Arnold Oronsky,
  Independent Director
• Albert Cha,
  Independent Director
• Brian Pereira,
  Independent Director
• Daniel Soland,
  Independent Director
• Michael Smith,
  Senior Vice President - Development
• Andreas Maetzel,
  Senior Vice President - Medical
• Jarrod Aldom,
  VP of Corp. Communications
• John B. McKune,
  VP of Fin.
• Stephen Donnelly,
  Director of Fin. and Company Sec.
• Dr. Paul K. Audhya M.B.A., M.D.,
  Chief Medical Officer
• Dr. Michael D. Smith Pharm.D.,
  Sr. VP of Devel.
• Rachel Morten,
  Head of Regulatory Affairs and QA
• Leah Monteiro,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Edward P. Feener Ph.D.,
  Chief Scientific Officer
• Joshua Resnick,
  Director
• Iv, Llcsv Life Sciences Fun...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, L.P.Ra ...,
  
• Rajeev M. Shah,
  Director
• Healthcare Capital Partners...,
  
• Holdings A/S Novo,
  10% owner
• William Fairey,
  
• Paul K. Audhya,
  CHIEF MEDICAL OFFICER
• Healthcare Capital Partners...,
  
• Nancy Stuart,
  Director
• Patrick Treanor,
  Director
• Brian Piekos,
  Chief Financial Officer
• Healthcare Capital Partners...,